DIAGNOS Announces a Pilot with Hospital Oftalmológico Buena Vista Sinaloa
June 15 2021 - 11:20AM
Diagnos Inc. (“
DIAGNOS” or the
“
Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF),
a leader in early detection of critical health issues, announces
today the signing of a 2-month pilot with Hospital Oftalmológico
Buena Vista Sinaloa, the largest ophthalmological hospital in
Sinaloa State, Mexico.
In Mexico there are 18
million diabetics with a 23% prevalence in people of 20
years or more; the seriousness of these cases is that every
hour in the country eight patients die from this disease, since 80%
of deaths in Mexico, is related to diabetes. In Sinaloa State,
355,000 thousand cases are reported, of which almost half (175,000)
are undiagnosed, with a prevalence of 21% of the population of 20
years or more. Of the 180,000 diagnosed for diabetes, only 30% go
to the doctor on a regular basis. According to statistics, 30,000
new cases of diabetes per year are registered in the State of
Sinaloa. Diabetic Retinopathy and loss of vision are the 2 biggest
problems.
“For almost 25 years, we’ve been providing
ophthalmic eye care to hundreds of thousands of patients coming
from 4 out of 9 States of the Northern Region of Mexico, mainly the
west pacific area. Our focus is to provide our specialty services
to everybody within one of our 7 eye health programs such as
Ophthalmological Consultation, Surgeries, Culture of Prevention of
Eye Diseases, Campaign of Free Consultation in Suburban Areas to
People in Extreme Poverty, National Museum of Ophthalmology, among
others”, mentions Dr. Efraín Romo Santos, Founder and Head
of Ophthalmology at Hospital Oftalmológico Buena Vista
Sinaloa. “We’re excited to welcome DIAGNOS as we look
forward to use a real-life tested technology based on AI, reliable
and compliant with the most exigent international standards”,
finished Dr. Romo.
“This is a great moment for DIAGNOS as we’ve
been proving that our AI and Telemedicine modules helps safety
issues around specialists and their staff during this challenging
time. We will be demonstrating our service of retina screening to
everyone that needs it”, says Mr. Guillermo Moreno, Vice
President of DIAGNOS. “Along with Dr. Romo, we’ll provide
a turn-key solution to his renowned team of specialists, we’re
confident that during the pilot, we’ll deliver a real-time result
to the local population by supporting the specialists in their day
to day. Finally, we will give hope to patients through the access
to eye screening with Dr. Romo’s Institutions”, finished Mr.
Moreno.
About Hospital Oftalmológico Buena Vista
Sinaloa
At Buena Vista Sinaloa we have been dedicated
for more than 24 years to providing efficient ophthalmic treatments
for the diagnosis and prevention of eye diseases to each of our
clients in Culiacán (HD), Los Mochis and Mazatlan, all three in
Sinaloa State, Mexico.
Buena Vista Sinaloa began activities on December
6, 1996, its founder Dr. Efraín Romo Santos, has managed to form an
institution with doctors and specialists in ophthalmology, as well
as with cutting-edge equipment to care for patients in different
states such as Sinaloa, Durango, Baja California Sur and
Sonora.
About DIAGNOS
DIAGNOS is a publicly traded Canadian
corporation dedicated to early detection of critical health
problems based on its FLAIRE Artificial Intelligence (AI) platform.
FLAIRE allows for quick modifying and developing of applications
such as CARA (Computer Assisted Retina Analysis). CARA’s image
enhancement algorithms provide sharper, clearer and
easier-to-analyze retinal images. CARA is a cost-effective tool for
real-time screening of large volumes of patients. CARA has been
cleared for commercialization by the following regulators: Health
Canada, the FDA (USA), CE (Europe), COFEPRIS (Mexico) and Saudi FDA
(Saudi Arabia).
Additional information is available at
www.diagnos.com and www.sedar.com
This news release contains forward-looking
information. There can be no assurance that forward-looking
information will prove to be accurate, as actual results and future
events could differ materially from those anticipated in these
statements. DIAGNOS disclaims any intention or obligation to
publicly update or revise any forward-looking information, whether
as a result of new information, future events or otherwise. The
forward-looking information contained in this news release is
expressly qualified by this cautionary statement.
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
For further information, please contact:
Mr. André Larente, President
DIAGNOS Inc.
Tel: 450-678-8882 ext. 224
alarente@diagnos.ca
Diagnos (TSXV:ADK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Diagnos (TSXV:ADK)
Historical Stock Chart
From Apr 2023 to Apr 2024